Eyenovia Drug Patent Portfolio
Eyenovia owns 2 orange book drugs protected by 5 US patents Given below is the list of Eyenovia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10588913 | Aqueous suspension agent containing glucocorticosteroid nanoparticles | 09 May, 2036 | Active |
| US11376262 | Method of treating an inflammatory or infectious disease | 09 May, 2036 | Active |
| US10839960 | Ophthalmic drug delivery | 15 Jul, 2031 | Active |
| US11398306 | Ophthalmic drug delivery | 15 Jul, 2031 | Active |
| US11839487 | Ophthalmic drug delivery | 15 Jul, 2031 | Active |
Latest Legal Activities on Eyenovia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eyenovia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 May, 2024 | US10839960 |
| Recordation of Patent eGrant | 12 Dec, 2023 | US11839487 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Dec, 2023 | US11839487 |
|
Email Notification
Critical
| 12 Dec, 2023 | US11839487 |
| Patent eGrant Notification | 12 Dec, 2023 | US11839487 |
| Mail Patent eGrant Notification | 12 Dec, 2023 | US11839487 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Dec, 2023 | US11839487 |
|
Email Notification
Critical
| 23 Nov, 2023 | US11839487 |
|
Issue Notification Mailed
Critical
| 22 Nov, 2023 | US11839487 |
|
Application Is Considered Ready for Issue
Critical
| 02 Nov, 2023 | US11839487 |
| Dispatch to FDC | 02 Nov, 2023 | US11839487 |
|
Issue Fee Payment Verified
Critical
| 01 Nov, 2023 | US11839487 |
|
Issue Fee Payment Received
Critical
| 01 Nov, 2023 | US11839487 |
| Supplemental Papers - Oath or Declaration | 23 Oct, 2023 | US11839487 |
|
Mail Notice of Allowance
Critical
| 06 Oct, 2023 | US11839487 |
Eyenovia's Family Patents
Eyenovia Drug List
Given below is the complete list of Eyenovia's drugs and the patents protecting them.
1. Clobetasol Propionate
Clobetasol Propionate is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10588913 | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
09 May, 2036
(11 years from now)
| Active |
| US11376262 | Method of treating an inflammatory or infectious disease |
09 May, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clobetasol Propionate's drug page
2. Mydcombi
Mydcombi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10839960 | Ophthalmic drug delivery |
15 Jul, 2031
(6 years from now)
| Active |
| US11398306 | Ophthalmic drug delivery |
15 Jul, 2031
(6 years from now)
| Active |
| US11839487 | Ophthalmic drug delivery |
15 Jul, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mydcombi's drug page